Abeona Therapeutics ABEOW 深 沪
已收盘 01-09 16:00:00 美东时间
0.0698
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0698
- 总市值 2.11亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.021
- 委 比 0.00%
- 总股本 30.28亿
- 历史最高 17.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.021
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted restricted stock equity awards to seven new employees, totaling up to 79,584 shares, which vest annually over three years. The company, focused on cell and gene therapies for serious diseases, recently launched ZEVASKYN®, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa.
2025-12-31 12:30
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
<p>Abeona Therapeutics Inc. announced the appointment of Mohamad Tabrizi as Senior Vice President and Chief Business Officer. Tabrizi will lead corporate strategy, business development, and operational efficiency. He brings extensive experience in strategic planning, venture capital, and corporate development, including successful transactions with major pharmaceutical companies. Previously, he held roles as a General Partner at Pandect Bioventur...
2025-12-15 12:30
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
Abeona Therapeutics announced the first commercial use of ZEVASKYN, the first autologous gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The treatment was administered at Lucile Packard Children’s Hospital Stanford. CEO Vish Seshadri expressed pride in this milestone and gratitude to the medical network. ZEVASKYN uses the COL7A1 gene to help produce functional type VII collagen, addressing a cr...
2025-12-08 12:30
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to two new non-executive employees, totaling up to 45,685 restricted shares. The shares vest equally over three years, contingent on continued employment. Abeona Therapeutics is a biopharmaceutical company focused on cell and gene therapies for serious diseases, with its lead product ZEVASKYN® for recessive dystrophic epidermolysis bullosa.
2025-12-01 12:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
2025-11-13 01:05
Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
Abeona Therapeutics shares are trading higher after the company reported better...
2025-11-13 00:52
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of $(0.63) per share
2025-11-12 20:31
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
What to Expect from Abeona Therapeutics's Earnings
Abeona Therapeutics (NASDAQ:ABEO) is gearing up to announce its quarterly earni...
2025-11-12 03:03
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to 11 new non-executive employees, totaling up to 71,035 shares. The shares vest annually over three years, contingent on continued employment. The company specializes in cell and gene therapies, with ZEVASKYN being its flagship product for treating wounds in patients with recessive dystrophic epidermolysis bullosa.
2025-11-03 12:30
